Stockreport

Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients [Yahoo! Finance]

Kiromic BioPharma, Inc.  (KRBP) 
PDF HOUSTON, April 24, 2024 BUSINESS WIRE Kiromic BioPharma, Inc. (OTCQB: KRBP) ("Kiromic" or the "Company") announces consistent favorable safety, tolerability, and effica [Read more]